{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27","upperLimit":"30","value":"28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"The MMSE is scored out of a maximum of 30 points. A score of \\>25 is considered normal, with scores \\<25 indicating different levels of cognitive impairment: mild (21-24) moderate (10-20), and severe (0-10).","dispersionType":"Full Range","groups":[{"description":"Induction treatment cycles with rituximab, high-dose methotrexate and leucovorin will be administered every 2 weeks for 6 cycles. Two additional consolidation cycles of high-dose methotrexate without rituximab will be administered at 4 weeks and 8 weeks following completion of the combined therapy.\n\nMethotrexate: 6000 mg/m\\^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.\n\nRituximab: 375 mg/m\\^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate\n\nLeucovorin: Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes","id":"OG000","title":"Rituximab, High-Dose Methotrexate & Leucovorin Treatment"}],"paramType":"MEDIAN","populationDescription":"Two participants were not evaluable. One participant received one cycle of therapy and one was not evaluable due to treatment failure.","reportingStatus":"POSTED","timeFrame":"up to 2.5 years","title":"Median Mini Mental Status Exam (MMSE) Score in Surviving Participants After Rituximab, High-Dose Methotrexate & Leucovorin ( R-HD-MTX) Treatment","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}